Skip to main content
Top
Published in: Pediatric Drugs 6/2008

01-11-2008 | Therapy In Practice

Management of Acute Kidney Injury in Children

A Guide for Pediatricians

Author: Professor Sharon P. Andreoli

Published in: Pediatric Drugs | Issue 6/2008

Login to get access

Abstract

Acute kidney injury (AKI; previously called acute renal failure) is characterized by a usually reversible increase in the blood concentration of creatinine and nitrogenous waste products and by the inability of the kidney to appropriately regulate fluid and electrolyte homeostasis. The incidence of AKI in children appears to be increasing and the etiology of AKI over the past decades has shifted from primary renal disease to multifactorial causes, particularly in hospitalized children. Renal failure can be divided into prerenal failure, intrinsic renal disease including vascular insults, and obstructive uropathies. The history, physical examination, and laboratory studies including a urinalysis and radiographic studies can establish the likely cause(s) of AKI.
Once intrinsic renal failure has become established, management of the metabolic complications of AKI requires meticulous attention to fluid balance, electrolyte status, acid-base balance, and nutrition. Many children with AKI will need renal replacement therapy to remove endogenous and exogenous toxins and to maintain fluid, electrolyte, and acid-base balance until renal function improves. Renal replacement therapy may be provided by peritoneal dialysis (PD), intermittent hemodialysis (HD), or hemofiltration with or without a dialysis circuit. Many factors — including the age and size of the child, the cause of renal failure, the degree of metabolic derangements, blood pressure, and nutritional needs — are considered in deciding when to initiate renal replacement therapy and which modality of therapy to use. The prognosis of AKI is highly dependent on the underlying etiology of the AKI. Children who have AKI as a component of multisystem failure have a much higher mortality rate than children with intrinsic renal disease. Recovery from intrinsic renal disease is also highly dependent on the underlying etiology of the AKI. Children who have experienced AKI from any cause are at risk for late development of renal failure long after the initial insult. Such children need life-long monitoring of their renal function, blood pressure, and urinalysis.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
3.
go back to reference Moghal NE, Brocklebank JT, Meadow SR. A review of acute renal failure in children: incidence, etiology and outcome. Clin Nephrol 1998; 49: 91–5PubMed Moghal NE, Brocklebank JT, Meadow SR. A review of acute renal failure in children: incidence, etiology and outcome. Clin Nephrol 1998; 49: 91–5PubMed
4.
go back to reference Karlowivz MG, Adelman RD. Nonoliguric and oliguric acute renal failure. Pediatr Nephrol 1995; 9: 718–22CrossRef Karlowivz MG, Adelman RD. Nonoliguric and oliguric acute renal failure. Pediatr Nephrol 1995; 9: 718–22CrossRef
5.
go back to reference Andreoli SP. Acute renal failure: clinical evaluation and management. In: Avner ED, Harmon WE, Nauidet P, editors. Chapter 64: pediatric nephrology. Baltimore (MD): Williams and Wilkins, 2004: 1233–54 Andreoli SP. Acute renal failure: clinical evaluation and management. In: Avner ED, Harmon WE, Nauidet P, editors. Chapter 64: pediatric nephrology. Baltimore (MD): Williams and Wilkins, 2004: 1233–54
6.
go back to reference Cataldi L, Leone R, Moretti U, et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: a case controlled study. Arch Dis Child Fetal Neonatal Ed 2005; 90: 514–9CrossRef Cataldi L, Leone R, Moretti U, et al. Potential risk factors for the development of acute renal failure in preterm newborn infants: a case controlled study. Arch Dis Child Fetal Neonatal Ed 2005; 90: 514–9CrossRef
7.
go back to reference Aggarwal A, Kumar P, Chowkhary G, et al. Evaluation of renal function in asphyxiated newborns. J Trop Pediatr 2005; 51: 295–9PubMedCrossRef Aggarwal A, Kumar P, Chowkhary G, et al. Evaluation of renal function in asphyxiated newborns. J Trop Pediatr 2005; 51: 295–9PubMedCrossRef
8.
go back to reference Airede A, Bello M, Werasingher HD. Acute renal failure in the newborn: incidence and outcome. J Paediatr Child Health 1997; 33: 246–9PubMedCrossRef Airede A, Bello M, Werasingher HD. Acute renal failure in the newborn: incidence and outcome. J Paediatr Child Health 1997; 33: 246–9PubMedCrossRef
9.
go back to reference Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis 2005; 45: 96–101PubMedCrossRef Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. Am J Kidney Dis 2005; 45: 96–101PubMedCrossRef
10.
go back to reference Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21: 931–4PubMedCrossRef Cuzzolin L, Fanos V, Pinna B, et al. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21: 931–4PubMedCrossRef
11.
go back to reference Fekkete A, Treszl A, Toht-Heyn P, et al. Association between heat shock protein 72 gene polymorphism and acute renal failure in neonates. Pediatr Res 2003; 54: 452–5CrossRef Fekkete A, Treszl A, Toht-Heyn P, et al. Association between heat shock protein 72 gene polymorphism and acute renal failure in neonates. Pediatr Res 2003; 54: 452–5CrossRef
12.
go back to reference Vasarhelyi B, Toth-Heyn P, Treszl A, et al. Genetic polymorphism and risk for acute renal failure in preterm infants. Pediatr Nephrol 2005; 20: 132–3PubMedCrossRef Vasarhelyi B, Toth-Heyn P, Treszl A, et al. Genetic polymorphism and risk for acute renal failure in preterm infants. Pediatr Nephrol 2005; 20: 132–3PubMedCrossRef
13.
go back to reference Treszl A, Toth-Heyn P, Koscic I. Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol 2002; 17: 713–5PubMedCrossRef Treszl A, Toth-Heyn P, Koscic I. Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol 2002; 17: 713–5PubMedCrossRef
14.
go back to reference Lip GYH, Churchill D, Beevers M, et al. Angiotensin converting enzyme inhibitors in early pregnancy. Lancet 1997; 350: 1446–8PubMedCrossRef Lip GYH, Churchill D, Beevers M, et al. Angiotensin converting enzyme inhibitors in early pregnancy. Lancet 1997; 350: 1446–8PubMedCrossRef
15.
go back to reference Martinovic J, Benachi A, Laurent N, et al. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001; 358: 241–3PubMedCrossRef Martinovic J, Benachi A, Laurent N, et al. Fetal toxic effects and angiotensin-II-receptor antagonists. Lancet 2001; 358: 241–3PubMedCrossRef
16.
go back to reference Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Eng J Med 2006; 354: 2443–6CrossRef Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Eng J Med 2006; 354: 2443–6CrossRef
17.
go back to reference Benini D, Fanos V, Cuzzolin L, et al. In utero exposure to nonsteroidal anti-inflammatory drugs: neonatal acute renal failure. Pediatr Nephrol 2004; 19: 232–5PubMedCrossRef Benini D, Fanos V, Cuzzolin L, et al. In utero exposure to nonsteroidal anti-inflammatory drugs: neonatal acute renal failure. Pediatr Nephrol 2004; 19: 232–5PubMedCrossRef
18.
go back to reference Badr KF, Ichikawa I. Prerenal failure: a deleterious shift from renal compensation to decompensation. N Engl J Med 1988; 319: 623–8PubMedCrossRef Badr KF, Ichikawa I. Prerenal failure: a deleterious shift from renal compensation to decompensation. N Engl J Med 1988; 319: 623–8PubMedCrossRef
19.
go back to reference Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643–53PubMedCrossRef Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44: 643–53PubMedCrossRef
20.
go back to reference van Bel F, Guit GL, Schipper J, et al. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991; 118: 621–6PubMedCrossRef van Bel F, Guit GL, Schipper J, et al. Indomethacin-induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr 1991; 118: 621–6PubMedCrossRef
21.
go back to reference Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988; 112: 805–10PubMedCrossRef Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988; 112: 805–10PubMedCrossRef
22.
go back to reference Gouyon JB, Guignard JP. Management of acute renal failure in newborns. Pediatr Nephrol 2000; 14: 1037–40PubMedCrossRef Gouyon JB, Guignard JP. Management of acute renal failure in newborns. Pediatr Nephrol 2000; 14: 1037–40PubMedCrossRef
23.
go back to reference Mathew OP, Jones AS, James E, et al. Neonatal renal failure: usefulness of diagnostic indices. Pediatrics 1980; 65: 57–60PubMed Mathew OP, Jones AS, James E, et al. Neonatal renal failure: usefulness of diagnostic indices. Pediatrics 1980; 65: 57–60PubMed
24.
go back to reference Ellis EN, Arnold WC. Use of urinary indexes in renal failure in the newborn. Am J Dis Child 1982; 136: 615–7PubMed Ellis EN, Arnold WC. Use of urinary indexes in renal failure in the newborn. Am J Dis Child 1982; 136: 615–7PubMed
25.
go back to reference Martin-Ancel A, Garcia-Alix A, Gaya F, et al. Multiple organ involvement in perinatal asphyxia. J Pediatr 1995; 127: 786–93PubMedCrossRef Martin-Ancel A, Garcia-Alix A, Gaya F, et al. Multiple organ involvement in perinatal asphyxia. J Pediatr 1995; 127: 786–93PubMedCrossRef
26.
go back to reference Abuelo JG. Renal failure caused by chemicals, foods, plants, animal venoms, and misuse of drugs. Arch Intern Med 1990; 150: 505–10PubMedCrossRef Abuelo JG. Renal failure caused by chemicals, foods, plants, animal venoms, and misuse of drugs. Arch Intern Med 1990; 150: 505–10PubMedCrossRef
27.
go back to reference Gagnadoux MF, Habib R, Gubler MC, et al. Long-term (15–25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996; 46: 39–41PubMed Gagnadoux MF, Habib R, Gubler MC, et al. Long-term (15–25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996; 46: 39–41PubMed
28.
go back to reference Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea associated hemolytic uremic syndrome: a systematic review, meta-analysis and meta-regression. JAMA 2003; 290: 1360–70PubMedCrossRef Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea associated hemolytic uremic syndrome: a systematic review, meta-analysis and meta-regression. JAMA 2003; 290: 1360–70PubMedCrossRef
29.
go back to reference Su C, Brandt LJ. Escherichia coli 0157:H7 infection in humans. Ann Intern Med 1995; 123: 698–714PubMed Su C, Brandt LJ. Escherichia coli 0157:H7 infection in humans. Ann Intern Med 1995; 123: 698–714PubMed
30.
go back to reference Andreoli SP, Bergstein JM. Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. J Pediatr 1982; 100: 541–5PubMedCrossRef Andreoli SP, Bergstein JM. Development of insulin-dependent diabetes mellitus during the hemolytic-uremic syndrome. J Pediatr 1982; 100: 541–5PubMedCrossRef
31.
go back to reference Andreoli SP, Bergstein JM. Acute rhabdomyolysis associated with hemolyticuremic syndrome. J Pediatr 1983; 103: 78–80PubMedCrossRef Andreoli SP, Bergstein JM. Acute rhabdomyolysis associated with hemolyticuremic syndrome. J Pediatr 1983; 103: 78–80PubMedCrossRef
32.
go back to reference Siegler RJ. The spectrum of extrarenal involvement in post-diarrheal hemolyticuremic syndrome. J Pediatr 1994; 125: 511–8PubMedCrossRef Siegler RJ. The spectrum of extrarenal involvement in post-diarrheal hemolyticuremic syndrome. J Pediatr 1994; 125: 511–8PubMedCrossRef
33.
go back to reference Andreoli SP. Pancreatic involvement in the hemolytic uremic syndrome. In: Kaplan BS, Trompeter R, Moak J, editors. The hemolytic uremic syndrome: thrombotic thrombocytopenia purpura. New York: Marcel Decker, 1992, 131–41 Andreoli SP. Pancreatic involvement in the hemolytic uremic syndrome. In: Kaplan BS, Trompeter R, Moak J, editors. The hemolytic uremic syndrome: thrombotic thrombocytopenia purpura. New York: Marcel Decker, 1992, 131–41
34.
go back to reference Lopez EL, Contrini MM, Devoto S, et al. Incomplete hemolytic uremic syndrome in Argentinean children with bloody diarrhea. J Pediatr 1995; 127: 364–7PubMedCrossRef Lopez EL, Contrini MM, Devoto S, et al. Incomplete hemolytic uremic syndrome in Argentinean children with bloody diarrhea. J Pediatr 1995; 127: 364–7PubMedCrossRef
35.
go back to reference Andreoli SP. The pathophysiology of the hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 1999; 8: 459–64PubMedCrossRef Andreoli SP. The pathophysiology of the hemolytic uremic syndrome. Curr Opin Nephrol Hypertens 1999; 8: 459–64PubMedCrossRef
36.
go back to reference Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930–6PubMedCrossRef Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342: 1930–6PubMedCrossRef
37.
go back to reference Safdar N, Said A, Sangnon RE, et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli 0157:H7 enteritis: a metal analysis. 2002; JAMA 288: 996–1001PubMedCrossRef Safdar N, Said A, Sangnon RE, et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli 0157:H7 enteritis: a metal analysis. 2002; JAMA 288: 996–1001PubMedCrossRef
38.
go back to reference Trachtman H, Cnaan A, Christen E, et al. Effects of an oral Shiga toxin-binding agent on diarrhea associated hemolytic uremic syndrome in children: a randomized clinical trial. JAMA 2003; 290: 1337–4PubMedCrossRef Trachtman H, Cnaan A, Christen E, et al. Effects of an oral Shiga toxin-binding agent on diarrhea associated hemolytic uremic syndrome in children: a randomized clinical trial. JAMA 2003; 290: 1337–4PubMedCrossRef
39.
go back to reference Askenazi DJ, Feig DI, Graham NM, et al. 1–5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006; 69: 184–9PubMedCrossRef Askenazi DJ, Feig DI, Graham NM, et al. 1–5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 2006; 69: 184–9PubMedCrossRef
40.
go back to reference Andreoli SP. Are children with a history of acute kidney injury at risk of later kidney disease? Nat Clin Pract Nephrol 2006; 2: 412–5PubMedCrossRef Andreoli SP. Are children with a history of acute kidney injury at risk of later kidney disease? Nat Clin Pract Nephrol 2006; 2: 412–5PubMedCrossRef
41.
go back to reference Basile DP, Donohoe D, Roethe K, et al. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term outcome. Am J Physiol 2001; 281: F887–9 Basile DP, Donohoe D, Roethe K, et al. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term outcome. Am J Physiol 2001; 281: F887–9
42.
go back to reference Rodriguez MM, Gomez A, Abitbol C, et al. Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr Nephrol 2005; 20: 945–9PubMedCrossRef Rodriguez MM, Gomez A, Abitbol C, et al. Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr Nephrol 2005; 20: 945–9PubMedCrossRef
43.
go back to reference Abitbol CL, Bauer CR, Montane B, et al. Long term follow up of extremely low birth weight infants with neonatal renal failure. Pediatr Nephrol 2003; 18: 887–93PubMedCrossRef Abitbol CL, Bauer CR, Montane B, et al. Long term follow up of extremely low birth weight infants with neonatal renal failure. Pediatr Nephrol 2003; 18: 887–93PubMedCrossRef
44.
go back to reference Polito C, Papale MR, LaManna AL. Long term prognosis of acute renal failure in the full term newborn. Clin Pediatr 1998; 37: 381–6CrossRef Polito C, Papale MR, LaManna AL. Long term prognosis of acute renal failure in the full term newborn. Clin Pediatr 1998; 37: 381–6CrossRef
45.
go back to reference Anochie I, Eke F. Acute renal failure in Nigerian children: Port Harcourt experience. Pediatr Nephrol 2005; 20: 1610–4PubMedCrossRef Anochie I, Eke F. Acute renal failure in Nigerian children: Port Harcourt experience. Pediatr Nephrol 2005; 20: 1610–4PubMedCrossRef
46.
go back to reference Olowu WA, Adelusola KA. Pediatric acute renal failure in southwestern Nigeria. Kidney Int 2004; 66: 1541–8PubMedCrossRef Olowu WA, Adelusola KA. Pediatric acute renal failure in southwestern Nigeria. Kidney Int 2004; 66: 1541–8PubMedCrossRef
47.
go back to reference Jenik AG, Ceriani CJM, Gorenstein E, et al. A randomized, double blind, placebo controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. Pediatrics 2000; 105: 849–53CrossRef Jenik AG, Ceriani CJM, Gorenstein E, et al. A randomized, double blind, placebo controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. Pediatrics 2000; 105: 849–53CrossRef
48.
go back to reference Bakr AF. Prophylactic theophylline to prevent renal dysfunction in term newborns exposed to perinatal asphyxia: a study in a developing country. Pediatr Nephrol 2005; 20: 1249–153PubMedCrossRef Bakr AF. Prophylactic theophylline to prevent renal dysfunction in term newborns exposed to perinatal asphyxia: a study in a developing country. Pediatr Nephrol 2005; 20: 1249–153PubMedCrossRef
49.
go back to reference Bhat M, Shah Z, Makidoomi MS, et al. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo controlled trial. 2006; J Pediatr 149: 180–3PubMedCrossRef Bhat M, Shah Z, Makidoomi MS, et al. Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo controlled trial. 2006; J Pediatr 149: 180–3PubMedCrossRef
50.
go back to reference Lemley KV. Can theophylline prevent the development of renal dysfunction in neonates with severe asphyxia? Nat Clin Pract Nephrol 2006; 2: 196–7PubMedCrossRef Lemley KV. Can theophylline prevent the development of renal dysfunction in neonates with severe asphyxia? Nat Clin Pract Nephrol 2006; 2: 196–7PubMedCrossRef
51.
go back to reference Denton MD, Chertow GM, Brady HR. “Renal-dose” dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996; 49: 14–7 Denton MD, Chertow GM, Brady HR. “Renal-dose” dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int 1996; 49: 14–7
52.
go back to reference Chertow GM, Sayegh MH, Allgren RL, et al. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Am J Med 1996; 101: 49–53PubMedCrossRef Chertow GM, Sayegh MH, Allgren RL, et al. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Am J Med 1996; 101: 49–53PubMedCrossRef
53.
go back to reference Cantarovich F, Rangoonwwala B, et al. High dose furosemide for established ARF: a prospective, randomized, double blind, placebo controlled trial. Am J Kid Dis 2004; 44: 402–9PubMed Cantarovich F, Rangoonwwala B, et al. High dose furosemide for established ARF: a prospective, randomized, double blind, placebo controlled trial. Am J Kid Dis 2004; 44: 402–9PubMed
54.
go back to reference Bellomo R, Chapman M, Finfers S, et al. Low dose dopamine in patients with early renal dysfunction: a placebo controlled trial. Clinical Trials Group. Lancet 2000; 356: 2139–2141; 2000PubMedCrossRef Bellomo R, Chapman M, Finfers S, et al. Low dose dopamine in patients with early renal dysfunction: a placebo controlled trial. Clinical Trials Group. Lancet 2000; 356: 2139–2141; 2000PubMedCrossRef
55.
go back to reference Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29: 1526–31PubMedCrossRef Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29: 1526–31PubMedCrossRef
56.
57.
go back to reference Lauschke A, Teichgraber UKM, Frei U, et al. “Low-dose” dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69: 1669–72PubMedCrossRef Lauschke A, Teichgraber UKM, Frei U, et al. “Low-dose” dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006; 69: 1669–72PubMedCrossRef
59.
go back to reference Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Int Med 2005; 142: 510–24PubMed Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Int Med 2005; 142: 510–24PubMed
60.
go back to reference Marthur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27: 1832–7CrossRef Marthur VS, Swan SK, Lambrecht LJ, et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27: 1832–7CrossRef
61.
go back to reference Landoni G, Biondi-Zoccai GGL, Tumlin JA. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49: 56–68PubMedCrossRef Landoni G, Biondi-Zoccai GGL, Tumlin JA. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49: 56–68PubMedCrossRef
62.
go back to reference Knoderer CA, Leiser JD, Nailescu C, et al. Fenoldopam for acute kidney injury in children. Pediatr Nephrol 2008; 23: 495–8PubMedCrossRef Knoderer CA, Leiser JD, Nailescu C, et al. Fenoldopam for acute kidney injury in children. Pediatr Nephrol 2008; 23: 495–8PubMedCrossRef
63.
go back to reference Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4: 1522–30PubMed Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4: 1522–30PubMed
64.
go back to reference Rodriguez-Soriano J. Potassium homeostasis and its disturbances in children. Pediatr Nephrol 1995; 9: 364–74PubMedCrossRef Rodriguez-Soriano J. Potassium homeostasis and its disturbances in children. Pediatr Nephrol 1995; 9: 364–74PubMedCrossRef
65.
go back to reference Malone TA. Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in very low birth weight infants. J Pediatr 1991; 118: 121–3PubMedCrossRef Malone TA. Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in very low birth weight infants. J Pediatr 1991; 118: 121–3PubMedCrossRef
66.
go back to reference Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990; 38: 869–72PubMedCrossRef Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990; 38: 869–72PubMedCrossRef
67.
go back to reference Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992; 20: 159–61PubMed Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. Am J Kidney Dis 1992; 20: 159–61PubMed
68.
go back to reference Andreoli SP. Acute and chronic renal failure in children. In: Gearhart JP, Rink RC, Mouriquand PDE, editors. Pediatric Urology. Philadelphia (PA): WB Saunders, 2001: 777–89 Andreoli SP. Acute and chronic renal failure in children. In: Gearhart JP, Rink RC, Mouriquand PDE, editors. Pediatric Urology. Philadelphia (PA): WB Saunders, 2001: 777–89
69.
go back to reference Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987; 9: 206–10PubMed Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987; 9: 206–10PubMed
70.
go back to reference Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310: 1079–84PubMedCrossRef Andreoli SP, Bergstein JM, Sherrard DJ. Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310: 1079–84PubMedCrossRef
71.
go back to reference Andreoli SP. Aluminum and bone diseases in children. In: Castells S, Fineberg L, editors. Metabolic bone disease in children. New York: Marcel Decker, 1990; 249 Andreoli SP. Aluminum and bone diseases in children. In: Castells S, Fineberg L, editors. Metabolic bone disease in children. New York: Marcel Decker, 1990; 249
72.
go back to reference Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 2006; 149: 746–54PubMedCrossRef Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 2006; 149: 746–54PubMedCrossRef
73.
go back to reference Viu V, Orrbine E, Rosychuk RJ, et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 2004; 19: 644–50CrossRef Viu V, Orrbine E, Rosychuk RJ, et al. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 2004; 19: 644–50CrossRef
74.
go back to reference Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2003; 2: 133–9PubMedCrossRef Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2003; 2: 133–9PubMedCrossRef
75.
go back to reference Goldstein SL, Somers MJG, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005; 67: 653–8PubMedCrossRef Goldstein SL, Somers MJG, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005; 67: 653–8PubMedCrossRef
76.
go back to reference Belsha CW, Kohaut EC, Warady BA. Dialytic management of childhood acute renal failure: a survey of North American pediatric nephrologists. Pediatr Nephrol 1995; 9: 361–3PubMedCrossRef Belsha CW, Kohaut EC, Warady BA. Dialytic management of childhood acute renal failure: a survey of North American pediatric nephrologists. Pediatr Nephrol 1995; 9: 361–3PubMedCrossRef
77.
go back to reference Andreoli SP. Renal failure in the neonate. In: Oh W, Guignard JP, Baumgart S, editors. Nephrology and fluid/electrolyte physiology: neonatology questions and controversies. Philadelphia (PA): Elsevier Inc., 2008: 208–24 Andreoli SP. Renal failure in the neonate. In: Oh W, Guignard JP, Baumgart S, editors. Nephrology and fluid/electrolyte physiology: neonatology questions and controversies. Philadelphia (PA): Elsevier Inc., 2008: 208–24
78.
go back to reference Mathews DE, West KW, Rescorla FJ, et al. Peritoneal dialysis in the first 60 days of life. J Pediatr Surg 1990; 25: 110–6CrossRef Mathews DE, West KW, Rescorla FJ, et al. Peritoneal dialysis in the first 60 days of life. J Pediatr Surg 1990; 25: 110–6CrossRef
79.
go back to reference Donckerwolcke RA, Bunchman TE. Hemodialysis in infants and small children. Pediatr Nephrol 1994; 8: 103–6PubMedCrossRef Donckerwolcke RA, Bunchman TE. Hemodialysis in infants and small children. Pediatr Nephrol 1994; 8: 103–6PubMedCrossRef
80.
go back to reference Al-Hermi BE, Al-Saran K, Secker D, et al. Hemodialysis for end-stage renal disease in children weighing less than 10 kg. Pediatr Nephrol 1999; 13: 401–3PubMedCrossRef Al-Hermi BE, Al-Saran K, Secker D, et al. Hemodialysis for end-stage renal disease in children weighing less than 10 kg. Pediatr Nephrol 1999; 13: 401–3PubMedCrossRef
81.
go back to reference Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45: 629–35PubMedCrossRef Arieff AI. Dialysis disequilibrium syndrome: current concepts on pathogenesis and prevention. Kidney Int 1994; 45: 629–35PubMedCrossRef
82.
go back to reference Bunchman TE, Maxvold NJ, Kershaw DB, et al. Continuous venovenous hemodiafiltration in infants and children. Am J Kidney Dis 1995; 25: 17–21PubMedCrossRef Bunchman TE, Maxvold NJ, Kershaw DB, et al. Continuous venovenous hemodiafiltration in infants and children. Am J Kidney Dis 1995; 25: 17–21PubMedCrossRef
83.
go back to reference Falk MC, Knight JF, Roy LP, et al. Continuous venovenous hemofiltration in the acute treatment of inborn errors of metabolism. Pediatr Nephrol 1994; 8: 330–3PubMedCrossRef Falk MC, Knight JF, Roy LP, et al. Continuous venovenous hemofiltration in the acute treatment of inborn errors of metabolism. Pediatr Nephrol 1994; 8: 330–3PubMedCrossRef
84.
go back to reference Smoyer WE, McAdams C, Kaplan BS, et al. Determinants of survival in pediatric continuous hemofiltration. J Am Soc Nephrol 1995; 6: 1401–9PubMed Smoyer WE, McAdams C, Kaplan BS, et al. Determinants of survival in pediatric continuous hemofiltration. J Am Soc Nephrol 1995; 6: 1401–9PubMed
85.
go back to reference Ellis EN, Pearson D, Belsha CW, et al. Use of pump-assisted hemofiltration in children with acute renal failure. Pediatr Nephrol 1997; 11: 196–200PubMedCrossRef Ellis EN, Pearson D, Belsha CW, et al. Use of pump-assisted hemofiltration in children with acute renal failure. Pediatr Nephrol 1997; 11: 196–200PubMedCrossRef
86.
go back to reference Maxvold NJ, Smoyer WE, Gardner JJ, et al. Management of acute renal failure in the pediatric patients: hemofiltration versus hemodialysis. Am J Kidney Dis 1997; 30: S84–8PubMedCrossRef Maxvold NJ, Smoyer WE, Gardner JJ, et al. Management of acute renal failure in the pediatric patients: hemofiltration versus hemodialysis. Am J Kidney Dis 1997; 30: S84–8PubMedCrossRef
Metadata
Title
Management of Acute Kidney Injury in Children
A Guide for Pediatricians
Author
Professor Sharon P. Andreoli
Publication date
01-11-2008
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2008
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/0148581-200810060-00005

Other articles of this Issue 6/2008

Pediatric Drugs 6/2008 Go to the issue

Acknowledgments

Acknowledgment